scholarly journals Humoral and Cellular Immunity to Varicella‐Zoster Virus: An Overview

2008 ◽  
Vol 197 (s2) ◽  
pp. S58-S60 ◽  
Author(s):  
Ann M. Arvin
Vaccines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1440
Author(s):  
Han Cao ◽  
Yunfei Wang ◽  
Ning Luan ◽  
Kangyang Lin ◽  
Cunbao Liu

Glycoprotein E (gE) is one of the most abundant glycoproteins in varicella-zoster virus and plays pivotal roles in virus replication and transmission between ganglia cells. Its extracellular domain has been successfully used as an antigen in subunit zoster vaccines. The intracellular C-terminal domain was reported to be decisive for gE trafficking between the endoplasmic reticulum, trans-Golgi network and endosomes and could influence virus spread and virus titers. Considering that the trafficking and distribution of mRNA vaccine-translated gE may be different from those of gE translated against the background of the viral genome (e.g., most gE in virus-infected cells exists as heterodimers with another glycoprotein, gI,), which may influence the immunogenicity of gE-based mRNA vaccines, we compared the humoral and cellular immunity induced by LNP-encapsulated mRNA sequences encoding the whole length of gE, the extracellular domain of gE and a C-terminal double mutant of gE (mutant Y569A with original motif AYRV, which targets gE to TGN, and mutants S593A, S595A, T596A and T598A with the original motif SSTT) that were reported to enhance virus spread and elevate virus titers. The results showed that while the humoral and cellular immunity induced by all of the mRNA vaccines was comparable to or better than that induced by the AS01B-adjuvanted subunit vaccines, the C-terminal double mutant of gE showed stable advantages in all of the indicators tested, including gE-specific IgG titers and T cell responses, and could be adopted as a candidate for both safer varicella vaccines and effective zoster vaccines.


Blood ◽  
1990 ◽  
Vol 75 (3) ◽  
pp. 806-809 ◽  
Author(s):  
S Kato ◽  
H Yabe ◽  
M Yabe ◽  
M Kimura ◽  
M Ito ◽  
...  

Abstract The transfer of antigen-specific cellular immunity in human bone marrow transplantation (BMT) was studied in 49 donor-recipient pairs, using a varicella-zoster-virus (VZV) specific lymphoproliferative response (LPR) assay. Posttransplant VZV-LPR could be serially measured in 31 long-term surviving recipients. VZV-specific T-cell immunity was detected in the early posttransplant period in 4 of 16 recipients who were, and whose donors were, immune to VZV before BMT, but two of those positive responses diminished in the first 100 days posttransplant. No positive response was detected in the immediate posttransplant period when either only the recipient or the donor was immune to VZV pretransplant. Herpes zoster or chickenpox developed in the recipients depending on a history of pretransplant VZV infection when the VZV-LPR became negative, and recovery from VZV infection was always followed by quick conversion of VZV-LPR. Long-lasting positive VZV-LPR was observed in the two recipients who experienced VZV infection in the immediate pretransplant period and received marrow graft from an immune donor. Our results indicate that a simple or direct transfer of VZV-specific cellular immunity from a marrow donor to a recipient cannot be expected in usual clinical bone marrow transplantation and that there might be a collaboration or recruitment of immune responses involving both donor and recipient that permits the VZV-LPR to remain positive posttransplant.


2014 ◽  
Vol 211 (4) ◽  
pp. 600-612 ◽  
Author(s):  
David Schub ◽  
Eva Janssen ◽  
Sarah Leyking ◽  
Urban Sester ◽  
Gunter Assmann ◽  
...  

1999 ◽  
Vol 180 (3) ◽  
pp. 834-837 ◽  
Author(s):  
Takuji Kumagai ◽  
Makoto Kamada ◽  
Chiharu Igarashi ◽  
Kenji Yuri ◽  
Hidetsugu Furukawa ◽  
...  

1998 ◽  
Vol 178 (s1) ◽  
pp. S104-S108 ◽  
Author(s):  
Michael Irwin ◽  
Carolyn Costlow ◽  
Heather Williams ◽  
Kamal Haydari Artin ◽  
Christina Y. Chan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document